After Going to Market | GenomeWeb

After Going to Market

Ruth Faden and her colleagues, who were part of an Institute of Medicine committee, examine the ethics of postmarketing research in a New England Journal of Medicine essay. Back in 2008, the US Food and Drug Administration told GlaxoSmithKline to look into whether its drug Avandia (rosiglitazone) was associated with a higher risk of heart attack and death as compared to placebo or other, unrelated drug therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.